These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21802905)

  • 1. Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling.
    Kato T; Yamashita T; Sekiguchi A; Tsuneda T; Sagara K; Takamura M; Kaneko S; Aizawa T; Fu LT
    J Cardiol; 2011 Sep; 58(2):131-6. PubMed ID: 21802905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition.
    Okazaki H; Minamino T; Tsukamoto O; Kim J; Okada K; Myoishi M; Wakeno M; Takashima S; Mochizuki N; Kitakaze M
    Hypertens Res; 2006 Apr; 29(4):277-84. PubMed ID: 16778335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat.
    Kato T; Yamashita T; Sekiguchi A; Tsuneda T; Sagara K; Takamura M; Kaneko S; Aizawa T; Fu LT
    J Cardiovasc Electrophysiol; 2008 Apr; 19(4):415-20. PubMed ID: 18298515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart.
    Tsutsui H; Matsushima S; Kinugawa S; Ide T; Inoue N; Ohta Y; Yokota T; Hamaguchi S; Sunagawa K
    Hypertens Res; 2007 May; 30(5):439-49. PubMed ID: 17587756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis.
    Jin D; Takai S; Sugiyama T; Hayashi T; Fukumoto M; Oku H; Kitaura Y; Ikeda T; Miyazaki M
    J Pharmacol Sci; 2009 Feb; 109(2):275-84. PubMed ID: 19202318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice.
    Shao JQ; Iwashita N; Du H; Wang YT; Wang YY; Zhao M; Wang J; Watada H; Kawamori R
    Acta Pharmacol Sin; 2007 Feb; 28(2):246-57. PubMed ID: 17241528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candesartan restores pressure-induced vasodilation and prevents skin pressure ulcer formation in diabetic mice.
    Danigo A; Nasser M; Bessaguet F; Javellaud J; Oudart N; Achard JM; Demiot C
    Cardiovasc Diabetol; 2015 Feb; 14():26. PubMed ID: 25888905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism.
    Dorenkamp M; Riad A; Stiehl S; Spillmann F; Westermann D; Du J; Pauschinger M; Noutsias M; Adams V; Schultheiss HP; Tschöpe C
    Eur J Pharmacol; 2005 Sep; 520(1-3):179-87. PubMed ID: 16139267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
    Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
    Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease--a dose-response relationship study.
    Saha SA; LaSalle BK; Clifton GD; Short RA; Tuttle KR
    Am J Ther; 2010; 17(6):553-8. PubMed ID: 19829095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade.
    Yaras N; Bilginoglu A; Vassort G; Turan B
    Am J Physiol Heart Circ Physiol; 2007 Feb; 292(2):H912-20. PubMed ID: 17012347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats.
    Soga M; Kamal FA; Watanabe K; Ma M; Palaniyandi S; Prakash P; Veeraveedu P; Mito S; Kunisaki M; Tachikawa H; Kodama M; Aizawa Y
    Int J Cardiol; 2006 Jun; 110(3):378-85. PubMed ID: 16324756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of candesartan cilexetil and amlodipine orotate on receptor for advanced glycation end products expression in the aortic wall of Otsuka Long-Evans Tokushima Fatty (OETFF) type 2 diabetic rats.
    Kang MK; Chung WB; Hong SK; Kim OR; Ihm SH; Chang K; Seung KB
    Arch Pharm Res; 2016 Apr; 39(4):565-576. PubMed ID: 26960737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.
    Iwamoto M; Hirohata S; Ogawa H; Ohtsuki T; Shinohata R; Miyoshi T; Hatipoglu FO; Kusachi S; Yamamoto K; Ninomiya Y
    Hypertens Res; 2010 Dec; 33(12):1305-11. PubMed ID: 20944640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of angiotensin II type 1 receptor on pathological remodeling and dysfunction in obstructed bladder.
    Aikawa K; Sakai T; Ishibashi K; Shiomi H; Sagawa K; Kumagai S; Kataoka M; Akaihata H; Yamaguchi O
    Int J Urol; 2012 May; 19(5):457-64. PubMed ID: 22320898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of AT1 receptors in permeability of the blood-brain barrier in diabetic hypertensive rats.
    Awad AS
    Vascul Pharmacol; 2006 Sep; 45(3):141-7. PubMed ID: 16959546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olmesartan attenuates type 2 diabetes-associated liver injury: Cross-talk of AGE/RAGE/JNK, STAT3/SCOS3 and RAS signaling pathways.
    Abo El-Nasr NME; Saleh DO; Mahmoud SS; Nofal SM; Abdelsalam RM; Safar MM; El-Abhar HS
    Eur J Pharmacol; 2020 May; 874():173010. PubMed ID: 32067934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.
    Shimano M; Tsuji Y; Inden Y; Kitamura K; Uchikawa T; Harata S; Nattel S; Murohara T
    Heart Rhythm; 2008 Mar; 5(3):451-9. PubMed ID: 18313605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
    Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
    Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function.
    Miller AG; Tan G; Binger KJ; Pickering RJ; Thomas MC; Nagaraj RH; Cooper ME; Wilkinson-Berka JL
    Diabetes; 2010 Dec; 59(12):3208-15. PubMed ID: 20852029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.